Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir.
Comparing the development of resistance to dolutegravir (DTG), bictegravir (BIC), and cabotegravir (CAB) using clinical isolates from treatment-naïve primary HIV infection (PHI) cohort participants
View Publication